Firms, Experts Allowed To Stay In AndroGel MDL

By Erin Marie Daly · May 18, 2011, 7:35 PM EDT

Solvay Pharmaceuticals Inc. and two other drugmakers on Tuesday lost bids to disqualify two expert witnesses and two law firms from multidistrict litigation in Georgia over whether the companies' AndroGel patent...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

order

Case Information

Case Title

IN RE: Androgel Antitrust Litigation (No. II)

Case Number

Court

Georgia Northern

Nature of Suit

Anti-Trust

Date Filed

October 05, 2009

Recent Articles By Erin

May 19, 2011
Genentech Sues Apotex Over Generic Valcyte
May 19, 2011
CORRECTED: Mylan's Inequitable Conduct Claim Axed In Vytorin IP Suit
May 10, 2011
Pharmacies Attack $68B Pfizer-Wyeth Deal In 9th Circ.
May 03, 2011
2nd Circ. Rejects Nurses Review Of Class Cert. Denial
April 27, 2011
Genzyme Sues Over Endo's Bid To Sell Generic Renvela
April 27, 2011
Asahi, Actelion Throw Final Punches In Fasudil IP Row
April 20, 2011
Novartis Targets Teva Over Myfortic Patents
April 13, 2011
HGS Fires Round 2 At Genentech Over Lupus Drug IP
April 13, 2011
MetroPlus, HHC Evade State Claims In OT Action
April 08, 2011
UK Court Shutters Merck's Cosopt Patent Fight